Lode H
Medizinische Klinik, Klinikum Steglitz, Freien Universität Berlin.
Schweiz Med Wochenschr. 1988 Dec 10;118(49):1823-30.
New quinolones are notable for their high level of antibacterial activity, especially against gram-negative pathogens, and also for their specific pharmacokinetics involving good bioavailability after oral administration, high distribution volumes and a long elimination time. In view of these properties the more recent quinolones can be regarded as on a par with the modern beta-lactam antibiotics and aminoglycosides, which, especially through the possibility of oral administration in infections with problem organisms such as Pseudomonas aeruginosa or Serratia, represent a therapeutic advance. To maintain this advance the indications for therapy must be approached in a restrictive and critical spirit; the newer quinolones are only rarely the drugs of choice and should be held in reserve for complicated infections of the respiratory tract, the intestinal tract, the urinary tract and the bones. In regard to tolerance, particular consideration should be given to the specific CNS intolerance reaction.
新型喹诺酮类药物以其高度的抗菌活性而著称，尤其是对革兰氏阴性病原体，并且其特定的药代动力学表现为口服后生物利用度良好、分布容积高以及消除时间长。鉴于这些特性，较新的喹诺酮类药物可被视为与现代β-内酰胺类抗生素和氨基糖苷类抗生素相当，特别是通过对铜绿假单胞菌或沙雷氏菌等难治性生物体感染进行口服给药的可能性，代表了一种治疗进展。为保持这一进展，治疗指征必须以严格和审慎的态度来对待；新型喹诺酮类药物很少是首选药物，应留作治疗呼吸道、肠道、泌尿道和骨骼的复杂感染。在耐受性方面，应特别考虑特定的中枢神经系统不耐受反应。
